ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1691

The Presence of Fibromialgia May Influence the Clinimetric Evaluation of Patients with Ankylosing Spondylitis, but Has No Impact on Disease Activity Assessment

Emilio Buschiazzo1, Natalia Zamora2, Fernando Andres Sommerfleck3, Romina Rojas Tessel4, Mariana Benegas5, Pablo Arturi6,7, Maria Elena Crespo4, Emilce Schneeberger8 and Gustavo Citera2, 1Rheumatology, Hospital Sr Del Milagro, Salta, Argentina, 2Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Rheumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Hospital Sr Del Milagro, Salta, Argentina, 5Sanatorio Mitre, Buenos Aires, Argentina, 6Rheumatology, Instituto de Rehabilitacion Psicofisica and Fundacion Reumatologica Argentina, Buenos Aires, Argentina, 7Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina, 8Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS), assessment and fibromyalgia, Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Fibromyalgia (FM) can be present concomitantly in patients with Ankylosing Spondylitis (AS). It may overestimate the evaluation of disease activity, resulting in more intensive treatment. The Objective of this study was to evaluate the influence of the concomitant presence of FM in the evaluation of patients with AS.

Methods:

Consecutive patients with AS (1984 New York criteria), were included. The presence of concomitant FM was assessed by both 1990 and 2010 ACR criteria. Data regarding sociodemographic characteristics (age, sex), disease duration, treatment, disease activity (BASDAI, ASDAS-ESR, SASDAS, global patient VAS), funcional capacity (BASFI), quality of life (ASQoL), enthesitis (MASES), tender and swollen 44/46 joint count, CRP and ESR, Fibromyalgia Impact Questionnaire (FIQ) was assessed. Categorical data was expressed in frequency and percentage and compared by chi2 or Fisher exact test, continuous data was expressed as median and interquartile range (IQR), and compared by Mann-Whitney-U-Test or Student’s T-Test. Multivariate analysis was performed taking activity indexes as dependent variables, adjusting for confounders. A p < 0.05 value was considered as significant.

Results:

50 patients were included, 44 (88%) male, median age 40 years (IQR 31-52), disease duration 9.1 years (IQR 2-20), 40 (80%) were treated with NSAIDs, 21 (42%) with TNF alpha blockers. Median BASDAI, ASDAS-ESR and SASDAS were 5.2 (IQR 1.8-6.9), 2.4 (IQR 1.7-3.6) and 19.4 (IQR 6.9-29.1) respectively. FM was present in 12 patients (24%), 7 (14%) and 6 (12%) fulfilled 2010 and 1990 criteria respectively, leaving only one patient overlapping both criteria. In the univariate analysis patients with FM had significantly higher values of disease activity scores, BASFI, ASQoL, FIQ, MASES, tender joints, patient’s VAS, number of fibrositic points, but similar ESR, CPR and swollen joint count. All the patients with FM were at the high or very high activity groups according to ASDAS-ESR / SASDAS. In the multivariate analysis, the presence of FM remained significantly associated with higher MASES and poorer ASQoL, but had lost influence in disease activity indexes (BASDAI, ASDAS-ESR nor SADAS).

Conclusion:

In our cohort of patients with AS enthesis evaluation by MASES and quality of life were significantly influenced by the presence of FM, but it had no impact on disease activity assessment.  In the evaluation of the enthesis it should be taken in account the coexistence of FM and AS in order to use more specific tools to evaluate them.


Disclosure: E. Buschiazzo, None; N. Zamora, None; F. A. Sommerfleck, None; R. Rojas Tessel, None; M. Benegas, None; P. Arturi, None; M. E. Crespo, None; E. Schneeberger, None; G. Citera, None.

To cite this abstract in AMA style:

Buschiazzo E, Zamora N, Sommerfleck FA, Rojas Tessel R, Benegas M, Arturi P, Crespo ME, Schneeberger E, Citera G. The Presence of Fibromialgia May Influence the Clinimetric Evaluation of Patients with Ankylosing Spondylitis, but Has No Impact on Disease Activity Assessment [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-presence-of-fibromialgia-may-influence-the-clinimetric-evaluation-of-patients-with-ankylosing-spondylitis-but-has-no-impact-on-disease-activity-assessment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-presence-of-fibromialgia-may-influence-the-clinimetric-evaluation-of-patients-with-ankylosing-spondylitis-but-has-no-impact-on-disease-activity-assessment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology